User menu

Economic aspects of treatment for fungal infections in cancer patients

Bibliographic reference Torfs, K. Economic aspects of treatment for fungal infections in cancer patients.Trends in Invasive Fungal Infections 3 Meeting (BRUSSELS(Belgium), Sep, 1995). In: European Journal of Clinical Microbiology & Infectious Diseases : an international journal on pathogenesis, diagnosis, epidemiology, therapy, and prevention of infectious diseases, Vol. 16, no. 1, p. 98-107 (1997)
Permanent URL
  1. Persson U, Tennvall GR, Andersson S, Tyden G, Wettermark B: Cost-effectiveness analysis of treatment with liposomal amphotericin B in organ or bone marrow transplant recipients with systemic mycoses. Pharmacoeconomics 1992, 2: 500–508.
  2. Schmitt H-J, New methods of delivery of amphotericin B. Clinical Infectious Diseases 1993, 17, Supplement 2: 501–506.
  3. De Marie S, Janknegt R, Bakker-Woudenberg I: Clinical use of liposomal and lipid-complexed amphotericin B. Journal of Antimicrobial Chemotherapy 1994, 33: 907–916.
  4. Goodman JL, Wiston DJ, Greenfeld RA, Chandrasekar PH, Fox B, Kaizer H, Shadduck RK, Shea TC, Stiff P, Friedman DJ, Powderly WG, Silber JL, Horowitz H, Lichtin A, Wolff SN, Mangan KF, Silver SM, Weisdorf D, Ho WG, Gillbert G, Buell D: A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. New England Journal of Medicine 1992, 326: 845–851.
  5. Winston DJ, Chandrasekar PH, Lazarus HM, Goodman JL, Silber JL, Horowitz H, Shadduck RK, Shea TC, Stiff P, Friedman DJ et al.: Fluconazole prophylaxis of fungal infections in patients with acute leukaemia. Annals of Internal Medicine 1993, 118: 495–503.
  6. Steward A, Powles R, Hewetson M, Antrum J, Richardson C, Metha J: Costs of antifungal prophylaxis after bone marrow transplantation. A model comparing oral fluconazole, liposomal amphoterici B and oral polyenes as prophylaxis against oropharyngeal infections. Pharmacoeconomics 1995, 8: 350–361.
  7. Williams C, Coyle D, Gray A, Hutton J, Jefferson T, Karlsson G, Kesteloot K, Uyl-de-Groot C, Wait S: European school of oncology advisory report to the Commission of the European Communities for the “Europe against Cancer Programme” cost-effectiveness in cancer care. European Journal of Cancer 1995, 31: 1410–1424.
  8. Commonwealth Department of Health, Housing and Community Services: Guidelines for the pharmaceutical industry on preparation of submissions to the Pharmaceutical Benefits Advisory Committee. Australian Government Publishing Service, Canberra, August 1992.
  9. Canadian Coordinating Office for Health Technology Assessment: Guidelines for economic evaluation of pharmaceuticals. CCOHTA, Ottawa, Canada, November 1994.
  10. Ministry of Health of Ontario: Ontario guidelines for economic analysis of pharmaceutical products. Ministry of Health, Toronto, Ontario, Canada, 1994.
  11. Clemens K, Townsend R, Luscombe F, Mauskopf J, Osterhaus J, Bobula J: Methodological and conduct principles for pharmacoeconomic research (PhRMA Pharmacoeconomics Guidelines). Pharmacoeconomic 1995, 8: 169–174
  12. Task Force on Principles for Economic Analysis of Health Care Technology: Economic analysis of health care technology. A report on principles, position paper. Annals of internal Medicine 1995, 122: 61–70.
  13. Drummond F, Stoddart G, Torrance GW: Methods for the economic evaluation of health care programmes. Oxford Medical Publications, Oxford, 1987, p. 95–104.
  14. Briggs A, Sculpher M: Sensitivity analysis in economic evaluation: a review of published studies. Health Economics 1995, 4: 355–371.
  15. Sloan FA: Introduction. In: Sloan FA (ed): Valuing health care: costs, benefits and effectiveness of pharmaceuticals and other medical technologies. Cambridge University Press, Cambridge, 1995.